Tyrosine kinase inhibitors have been shown to have significant therapeutic utility in non-small cell lung cancer; however, they also developed drug resistance during treatment due to paxillin-mediated ERK activation to reduce the interaction of Bcl2 with cell death mediators and to increase Mcl-1 expression [182]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.